SSO Bio announced the completion of nearly RMB300 million round D financing

On December 8, 2020, after completing nearly 600 million yuan of C-round financing in the first half of the year, precision medicine company Soyuan Bio announced that it had just completed nearly 300 million yuan of round D financing.
The current round of financing by THEC Qide Fund and PCCW Capital co-led investment, China Resources Pharmaceutical Industry Investment Fund, Paradise Silicon Valley, Anda Biopharmaceutical Fund, Fangyu Fund, Chengdu Bedojian and Hangshi Capital Management, etc. to join the new shareholder lineup, the existing shareholders Xianyu Capital, Houxin Jian Investment and Zhejiang Commercial Andirong to participate.
is a new type of international enterprise that develops a new class of new drugs in a unique model that is fast and effective.
currently has seven products (DB102 - DB108) that have been developed in the field of oncology and psychotic diseases, all of which are the world's first-in-class or a class of new drugs.
they are: DB102 (enzastaurin), an international multi-center clinical Phase 3 trial for first-line treatment of diffuse large B-cell lymphoma (DLBCL), has been completed in all patients, and the international multi-center clinical Phase 3 trial for the treatment of newly diagnosed cerebroglioblastoma (GBM) has been approved by the FDA and the National Drug Administration of China (NMPA) and fully launched in the United States and China.
, the FDA also granted it fast-track eligibility for first-line treatment for GBM.
DB103, a drug developed to treat schizophrenia, was introduced from Eli Lilly and Company and targeted at glutamate-intransegion.
multi-center clinical trial of the drug was approved by the State Drug Administration of China at the end of 2018 and clinical studies are currently under way.
liafensine, an antidepressant obtained from ARMI/BMS.
DB105 is a selective, potent, brand new antagonist with a target of α-2C epinephrine-on-the-adrenaline -AR, developed for the treatment of Alzheimer's disease.
the drug was originally developed by Finland's Olion Group and currently has a global interest in the drug.
, in December 2019 announced that it had obtained global rights to the "first-in-class" anti-tumor drug from Sunes pharmaceuticals in the United States.
it is a powerful, non-cyclic topological isomerase II inhibitor that can be used in tumor therapy, such as acute myeloid leukemia (AML) and solid tumors.
more than 1,200 patients in 16 clinical studies have been given vosaroxin, confirming its controlled safety and potential efficacy, according to a press release at the time.
DB107, Soryuan Bio announced in April that it would acquire the core assets of Tocagen, a gene therapy company, including a global interest in the gene therapy platform and all related product pipelines (except for one product greater China equity).
acquisition includes Toca 511 and Toca FC (now known as DB107), Tocagen's pharmaceutical portfolio for phase 3 clinical treatment of relapsed high-level gliomas, as well as several early-stage oncology immunotherapy projects.
DB107 is a "first-in-class" product in the study, it cleverly combines advanced gene therapy with traditional drugs for the treatment of brain tumors and other malignancies, and has been recognized by the FDA breakthrough therapy.
DB108, So yuan bio just a week ago (December this year) announced the acquisition of Wu Traditional Chinese medicine class 1 anti-cancer new drug recombinant human vascular endotrhoids (now named DB108) outside china's global rights.
, DB108 is the first large-molecule biopharmaceity drug for sornot organisms, according to a press release.
is a recombinant protein drug that inhibits tumor growth and metastasis by inhibiting angiogenesic production.
source: Medical Mission Hills, focus on the "Pharmaceutical Mingkang" WeChat public number